Therefore, we believe that ongoing in vitro studies focusing on blocking the PI3K/AKT/mTOR /NF-kB pathways would be interesting and provide promising results that may enhance the efficiency of anti-cancer therapeutics. This evidence concerns the gene AKT1 and cancer.